Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How To Make A Global First-In-Class Drug In China

Executive Summary

The story so far of how an aspiring Western returnee researcher became a fully charged pharma entrepreneur in China’s wild world of drug innovation.

You may also be interested in...



Fifth PD-1, Zavicefta, Novel Psoriasis Ointment Among Latest China Approvals

Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.

Betta IPO: New Hope For Made In China Innovation?

The successful IPO of China's drug innovation darling Betta may herald a new wave of capital inflow and renewed interest in new drug R&D in China, but hurdles to the pursuit of original research remain.

BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue

The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.

Topics

Related Companies

UsernamePublicRestriction

Register

SC098260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel